Lion Biotechnologies Inc (NASDAQ:LBIO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Thursday. According to Zacks, “Lion Biotechnologies, Inc. is developing autologous cell therapies for the treatment of cancer. The Company’s lead product candidate, C?ntego(TM), is an autologous cell therapy indicated for the treatment […]
